Our News

Twogene Co., Ltd. Reaches Understanding with King Mongkut’s University ofTechnology Thonburi for Cell and Gene Therapy Production Facility

Twogene Co., Ltd. (Twogene), a new  Contract Development and Manufacturing Organization (CDMO) established by an  international consortium of life science entrepreneurs and focusing on cell and gene  therapy (CGT) and plasmid DNA, has reached a Letter of Intent (LOI) with King Mongkut’s  University of Technology Thonburi (KMUTT) for a long-term lease of the National  Biopharmaceutical Facility (NBF) on microbial and cell culture production platforms. 

This understanding heralds a significant step forward in the collaboration between  Twogene and KMUTT, aimed at enhancing the production of Advanced Therapy  Medicinal Products (ATMPs). The goal of this cooperation is to promote Thai life science  capabilities for global application, particularly in the advanced sector of cell and gene  therapy. 

“We are proud to foster a partnership that leverages our strong capabilities in life  sciences at KMUTT. Collaborating with Twogene in this state-of-the-art facility not only  marks a significant milestone in our university’s commitment to biotechnological  advancements but also paves the way for groundbreaking discoveries and innovations in  the field of bioprocessing of cell and gene therapy,” said Assoc. Prof. Dr. Suvit Sae TiaPresident of King Mongkut’s University of Technology Thonburi

“The LOI with KMUTT is a testament to our commitment to advancing the field of ATMPs.  Leveraging the National Biopharmaceutical Facility will not only boost our production  capacities but also aligns with our goal to position Thailand as a key player in the global  life science and biopharmaceutical industry,” said Bertrand Coissac, Co-founder of  Twogene

About King Mongkut’s University of Technology Thonburi (KMUTT) 

King Mongkut’s University of Technology Thonburi (KMUTT), established in 1960, is a  leading science and technological university in Thailand known for its strong emphasis  on engineering, technology, and innovation.  

In addition to its renowned engineering and technology programs, KMUTT has also made  significant strides in the field of life sciences. The university actively fosters research and 

development in biotechnology, contributing to advancements not only in food, feed,  biofuel, but also healthcare and biopharmaceutical applications. 

Renowned for its rigorous academic programs and research initiatives, KMUTT  collaborates with top tier international institutions, fostering a global perspective among  its students and faculty. The university’s commitment to research and development in  cutting-edge technologies has positioned it as a pivotal player in driving Thailand’s  technological competitiveness, economic growth and sustainability. 

With state-of-the-art facilities and a vibrant campus life, KMUTT offers an environment  that nurtures creativity, critical thinking, practical skills and entrepreneurial mindset,  preparing its graduates to become leaders in their respective fields. The university’s  focus on sustainable development and community engagement further underscores its  role as a responsible and forward-thinking institution. 

For more information, visit www.kmutt.ac.th

About the National Biopharmaceutical Facility (NBF): 

NBF was initiated in 2008 as a collaboration between the National Center for Genetic  Engineering and Biotechnology (BIOTEC)/National Science and Technology Development  Agency (NSTDA) and KMUTT. It represents a significant cooperative effort between these  institutions. Located at the Bangkhunthian Campus of KMUTT, NBF is Thailand’s premier  facility for the manufacturing of clinical-grade biopharmaceuticals, particularly for first 

in-human studies. It is equipped with state-of-the-art technology, including microbial and  cell culture fermentation systems, both of which can accommodate up to 500 liters. The  facility also meets the Biosafety Level 2 (BSL2) standards, ensuring a safe and controlled  environment for biopharmaceutical research and production. As Thailand’s first state 

owned contract manufacturing facility specializing in the production of clinical research grade biopharmaceuticals, NBF stands as a center of excellence in science and  technology. Its establishment underlines Thailand’s commitment to self-reliance in the  production of drugs and positions the country as a key player in the biopharmaceutical  sector. 

About Twogene Co., Ltd. 

Founded in 2023 by an international consortium of life science entrepreneurs, Twogene  Co., Ltd, is a pioneering contract development and manufacturing organization (CDMO)  in Bangkok, Thailand. Focused on reshaping Southeast Asia’s bioprocessing landscape, 

Twogene specializes in process development and large-scale production of plasmid DNA  (pDNA) and proteins. Adhering to the highest global standards of quality and compliance,  Twogene is dedicated to transforming research into GMP-grade manufacturing. For more  information, visit www.twogene.com.

Share the Post: